N
154.03
-0.03 (-0.02%)
| 前收盘价格 | 154.06 |
| 成交量 | 1,741,063 |
| 预期市盈率 (P/E Forward) | 23.04 |
| 价格/销量 (P/S) | 4.78 |
| 股市价格/股市净资产 (P/B) | 4.29 |
| 52周波幅 |
| 营业毛利率 | 12.68% |
| 营业利益率 (TTM) | 4.14% |
| 稀释每股收益 (EPS TTM) | 2.95 |
| 季度收入增长率 (YOY) | 11.10% |
| 季度盈利增长率 (YOY) | -81.80% |
| 总债务/股东权益 (D/E MRQ) | 19.45% |
| 流动比率 (MRQ) | 3.13 |
| 营业现金流 (OCF TTM) | 529.90 M |
| 杠杆自由现金流 (LFCF TTM) | 235.48 M |
| 资产报酬率 (ROA TTM) | 8.75% |
| 股东权益报酬率 (ROE TTM) | 12.43% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Drug Manufacturers - Specialty & Generic (US) | 混合的 | 看涨 |
| Drug Manufacturers - Specialty & Generic (全球的) | 混合的 | 看涨 | |
| 股票 | Neurocrine Biosciences, Inc. | 混合的 | 看涨 |
AIStockmoo 评分
1.0
| 分析师共识 | NA |
| 内部交易活动 | NA |
| 价格波动 | 2.0 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | -0.5 |
| 平均 | 1.00 |
|
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. |
|
| 部门 | Healthcare |
| 行业 | Drug Manufacturers - Specialty & Generic |
| 投资方式 | Mid Core |
| 内部持股比例 | 1.06% |
| 机构持股比例 | 98.86% |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合